Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.

Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.

Oral JAK inhibitors help regrow hair in alopecia patients.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Mutations in the androgen receptor gene cause different levels of androgen insensitivity, making it hard to create simple tests for the condition.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

Mutations in the hHb6 gene cause the hair disorder monilethrix.

JAK inhibitors offer new hope for treating severe alopecia areata.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

Connexin mutations can cause various diseases like hearing loss and skin disorders.

A new mutation in the hHb1 keratin gene is linked to the hair disorder monilethrix.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

A mutation in the hHb3 gene is linked to the hair disorder monilethrix.

The document concludes that the human keratin gene cluster is complex, with a need for updated naming to reflect over 50 functional genes important for hair and skin biology.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

The document concludes that Borrelia afzelii causes a skin condition in France, a gene is linked to hair loss in Caucasian women, and various genetic mutations affect skin diseases.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

The E413K mutation in the hHb6 gene causes monilethrix, a hair disorder, but doesn't show consistent symptoms.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

The risk of skin tumors becoming malignant depends on the specific skin cell type affected.

A mutation in the KRT25 gene causes woolly hair and hair loss.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Inhibiting TYK2 can restore hair growth in alopecia areata.

CD2 might be a new treatment target for patchy alopecia areata.

Akt2 protein is essential for normal cell division in early mouse embryos.

A specific gene variant may increase the risk of developing Alopecia Areata.